机构：[1] Unaniv Chinese Med Guangzhou, Affiliated Hosp 2, Chinese Med Hosp Guangdong Prov, Dept Neurosurg, Gugzhou, Peoples R China[2] Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Int Expt Cent Nervous Syst Injury & Repair IECNSI, S-75185 Uppsala, Sweden[3] Hangzhou Hosp Tradit Chinese Med, Hangzhou, Peoples R China[4] Zhejiang Chinese Med Univ, Guangxing Affiliated Hosp, Hangzhou, Peoples R China[5] Guangzhou Huashang Vocat Coll, Guangzhou, Peoples R China[6] Guangdong Sanjiu Brain Hosp, Guangzhou, Peoples R China
Objective: To provide evidence for the mechanism of Chinese medicine to treat glioma. We observe the effects of Si wei xiao xiu yin combined with chemotherapy on the growth of subcutaneous xenografts in nude mice and the expression of miRNA-21 and miRNA-221 in tumor tissues. Methods: The subcutaneous transplantation model of nude mice was established by subcutaneous inoculation of glioma U87 cell suspension. They were randomly divided into saline group, traditional Chinese medicine group, temozolomide group and traditional Chinese medicine combined with temozolomide group to observe the changes in body weight, and the tumor weight, length, short diameter, volume of mice. The relative expression levels of miRNA-21 and miRNA-221 in tumor tissues were detected by qRT-PCR, and the differences between groups were compared. Results: After 28 days of gavage, the tumor growth of the other three groups was slower than that of saline group, and the difference was most significant in the combination group (P = 0.008 < 0.05), besides, the relative expression of the three groups of miRNA-21 and miRNA-221 was significantly inhibited compared with saline group, and the difference was significant in the combination group (F = 8.918, P = 0.010 < 0.05). Conclusion: To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice. The mechanism may be related to the inhibition of miRNA-21 and miRNA-221 expression.
基金：
The authors were supported by Science and Technology Planning Project of Guangdong
Province, China (Number: 2014A020212411).
第一作者机构：[1] Unaniv Chinese Med Guangzhou, Affiliated Hosp 2, Chinese Med Hosp Guangdong Prov, Dept Neurosurg, Gugzhou, Peoples R China[*1]Univ Chinese Med Guangzhou, Affiliated Hosp 2, Chinese Med Hosp Guangdong Prov, Dept Neurosurg, Guangzhou, Peoples R China
通讯作者：
通讯机构：[1] Unaniv Chinese Med Guangzhou, Affiliated Hosp 2, Chinese Med Hosp Guangdong Prov, Dept Neurosurg, Gugzhou, Peoples R China[*1]Univ Chinese Med Guangzhou, Affiliated Hosp 2, Chinese Med Hosp Guangdong Prov, Dept Neurosurg, Guangzhou, Peoples R China[2] Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Int Expt Cent Nervous Syst Injury & Repair IECNSI, S-75185 Uppsala, Sweden[*2]Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Int Expt Cent Nervous Syst Injury & Repair IECNSI, S-75185 Uppsala, Sweden
推荐引用方式(GB/T 7714)：
Zhang Zhiqiang,Chen Yun,Chen Huijing,等.New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221[J].NOVEL THERAPEUTIC ADVANCES IN GLIOBLASTOMA.2020,151:99-110.
：